Table 2 Clinical and laboratory differences between relapsing and non-relapsing visceral leishmaniasis patients

Sex (M/F)

8/2

4/1

NA

Age (years)

38 (30.8–46.5)

44 (30–61)

0.49

Total number of VL episodes (n)

1

3 (2–5)

NA

Accumulated dose of Amph. B in the current active VL phase (mg/kg)

20 (20–22.5)

25 (20–40)

0.24

C-reactive protein (mg/dL)

72 (42.3–154.5)

54.5 (39.5–174.5)

0.76

Platelet (x10³cel/mm³)

68 (42.8–80.8)

107 (88–216.5)

0.01

Aspartate aminotransferase (U/L)

69.5 (56.8–195.8)

38 (24–79)

0.03

Total bilirubin (mg/dL)

0.9 (0.7–1.0)

0.5 (0.5–0.8)

0.03